• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Baxter closes $625m Claris Injectables buy

July 27, 2017 By Sarah Faulkner

BaxterBaxter (NYSE:BAX) said today that it closed its $625 million acquisition of Claris Lifesciences‘ (BOM:533288) injectable drug biz.

According to the deal, Baxter gains Claris’ portfolio of injectable generics and three manufacturing plants. The Deerfield, Ill.-based company said it plans to add new aseptic manufacturing and lyophilization capabilities, as well as invest in new technology platforms, including cytotoxics.

The acquisition is expected to add at least 50 products to Baxter’s portfolio this year, the company reported.

“This acquisition reinforces our commitment to establishing Baxter as a global leader in generic injectable medicines,” chairman & CEO José Almeida said in prepared remarks. “The combination of Baxter and Claris Injectables will allow us to increase access to lower-cost generic injectables and strengthen our ability to meet the needs of healthcare providers and patients around the world.”

The buyout was financed with a combination of cash on hand and debt. Last year, Claris Injectables brought in $112 million in sales.

Last week, the Federal Trade Commission gave its official nod for the deal, but mandated that the companies divest two drugs products – an antifungal agent, fluconazole, and intravenous milrinone.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Baxter International, Claris Lifesciences

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS